Uridine triacetate

Drug Profile

Uridine triacetate

Alternative Names: PN 401; TAU; Triacetyluridine; Vistogard; Vistonuridine; Xuriden

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wellstat Therapeutics Corporation
  • Class Antidepressants; Chemoprotectants; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Adenosine triphosphatase stimulants; Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Orotic aciduria; Poisoning; Mitochondrial disorders
  • New Molecular Entity No

Highest Development Phases

  • Marketed Orotic aciduria; Poisoning
  • Phase III Pancreatic cancer
  • Phase II Gastric cancer
  • No development reported Neurodegenerative disorders
  • Discontinued Diabetic neuropathies

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Neurodegenerative-disorders in USA (PO)
  • 08 Sep 2016 Wellstat Therapeutics completes a phase III trial in Orotic-aciduria (In infants, In children, In adolescents, In adults) in USA (NCT02110147)
  • 23 Aug 2016 Launched for Orotic-aciduria in USA (PO) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top